Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

December 13, 2019

Study Completion Date

February 25, 2020

Conditions
Coronary Artery DiseaseCoronary Artery StenosesValve Regurgitation, MitralValve Regurgitation, Tricuspid
Interventions
DRUG

Exparel Injectable Product

Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)

DRUG

Bupivacaine Hydrochloride

Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)

Trial Locations (1)

15213

UPMC Presbyterian Hospital, Pittsburgh

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

Kathirvel Subramaniam

OTHER